PulsePoint for Opioid Overdose
(PP-OD Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What data supports the effectiveness of the treatment PulsePoint for opioid overdose?
The research highlights the importance of rapid response systems and technologies in addressing opioid overdoses, which are time-sensitive emergencies. While PulsePoint is not directly mentioned, similar systems have been shown to be effective in reversing overdoses when naloxone is administered quickly.12345
Is PulsePoint for Opioid Overdose safe for humans?
How does the PulsePoint treatment for opioid overdose differ from other treatments?
The PulsePoint treatment for opioid overdose is unique because it likely involves a community-based approach, similar to the modified community trailer model, which provides on-site harm reduction, addiction care, and community resources, rather than just emergency medical intervention. This approach may help reduce the burden on emergency departments and provide more comprehensive support for individuals experiencing an overdose.12101112
What is the purpose of this trial?
This study is a feasibility trial to assess whether, in a random sample of 180 agencies where PulsePoint is already active, revised procedures (hereinafter PulsePoint-OD) to facilitate opioid overdose and naloxone distribution (OEND) can successfully recruit first responder agencies and layperson responders. For this study, agency refers to a single implementation site where PulsePoint is active and that is bound by the service area or jurisdiction of the first responder agency collaborating with PulsePoint.The study will test the following hypotheses:H1: more first responder agencies will be successfully recruited by arm 2 than by arm 1.H2: more layperson responders will report engaging with OEND programming in arm 2 than in arms 1 or 3 and in arm 1 than in arm 3 \[only this hypothesis is covered by the IRB, hypothesis 1 is not human subjects research\].
Research Team
Jon Agley
Principal Investigator
Indiana University
Eligibility Criteria
This trial is for layperson responders registered with a local first responder agency through the PulsePoint system. It includes those who are alerted to incidents in public spaces and does not collect personal information beyond device ID.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive customized or standard messaging to facilitate opioid overdose education and naloxone distribution
Follow-up
Participants are monitored for engagement and certification in OEND programming
Treatment Details
Interventions
- PulsePoint
Find a Clinic Near You
Who Is Running the Clinical Trial?
Indiana University
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator